subject area of
- A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer Journal Articles
- A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia Journal Articles
- A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172) Journal Articles
- A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150 Journal Articles
- Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review Journal Articles
- Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group Journal Articles
- Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group Journal Articles
- Bortezomib in Multiple Myeloma: A Practice Guideline Journal Articles
- Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia Journal Articles
- Bortezomib protects from varicose‐like venous remodeling Journal Articles
- Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma Journal Articles
- Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells Journal Articles
- Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma Journal Articles
- Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis Journal Articles
- Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle Journal Articles
- Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database Journal Articles
- Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers Journal Articles
- Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database Journal Articles
- WTAP and m6A-modified circRNAs modulation during stress response in acute myeloid leukemia progenitor cells Journal Articles